Providing New Predictive Insights into Cell Therapy Process Development and Manufacturing Outcomes
In cell therapy, administering live cells to heal or cure is just the beginning—the real challenge lies in maintaining consistency and quality across the manufacturing lifecycle. Critical assays, like cell viability and function profiling, serve as the foundation for process control, regulatory compliance, and clinical confidence.
One form of cell therapy is using cells from the patient’s own body, modified either ex-vivo or within their native environment, called autologous therapy. Several autologous chimeric antigen receptor (CAR)-T cell therapies have been approved by the FDA and many more are the subject of ongoing clinical trials. The other major type of cell therapy is called allogeneic therapy wherein cells are removed from an individual donor source and then manufactured for many patients and available “off-the-shelf”. The ultimate goal for allogeneic therapies for many is the biomanufacturing of products from multiple donor sources, which are then pooled together in quantity and modified or processed before administration to other patients. Cell therapies include blood transfusions, stem cell transplants, gene modification cell therapy, and induced pluripotent stem cell (iPSC) therapy.
Challenges in Cell Therapy Development
Overcoming Analytical Complexity in Cell Therapy Development
Cell therapy offers transformative potential—but realizing that potential demands rigorous control over the quality, purity, and potency of therapeutic cells. From early-stage development to commercial-scale manufacturing, scientists face critical challenges including:
- Cellular heterogeneity across donors and patient populations.
- Precise characterization and monitoring throughout expansion and downstream processing.
- Global regulatory alignment for consistent, scalable production.
The innate variability of patient-derived cells introduces complexity at every stage, increasing the risk of inconsistency and diminishing therapeutic efficacy. Without advanced, reliable analytics, producing safe, high-quality treatments becomes a daunting task.
LumaCyte’s precision analytical tools empower teams to overcome these challenges, streamline quality assurance, and accelerate regulatory confidence.
Ready to advance your cell therapy program? Partner with LumaCyte.
Radiance® Revolutionizes Cell Therapy Analysis
LumaCyte’s Radiance® platform is transforming cell therapy analytics through real-time, label-free, predictive insights. Powered by proprietary Laser Force Cytology™ (LFC) technology, Radiance® enables researchers and manufacturers to streamline workflows, minimize delays, and ensure consistent, high-quality therapies.
Analytical Capabilities That Matter
- T Cell Activation and CAR-T Potency Assays: Monitor immune responses with accuracy to drive robust therapeutic outcomes.
- Cell Expansion Tracking: Achieve optimal growth and differentiation with real-time monitoring.
- Cell Health Profiling: Quantify cellular activity—including activation, killing efficiency, and differentiation—across key development phases.
Driving Better Outcomes in Manufacturing
- Rapid assessment of cellular starting material improves batch consistency.
- Early detection of production issues saves time and critical resources.
- Enhanced safety, potency, and reliability across complex workflows.
Radiance® delivers deeper insights into cellular responses, helping accelerate the delivery of life-saving treatments with higher quality and precision. This innovation redefines the analytical standards for cell therapy manufacturing and supports the development of safe, effective therapies.
By leveraging Laser Force Cytology™ (LFC) technology, Radiance® ensures real-time insights into cell conditions, reducing unnecessary bottlenecks and delays. Manufacturers can rapidly assess the quality of starting materials and improve batch consistency:
- Save valuable resources by identifying issues early.
- Deliver life-saving treatments faster to patients.
- Ensure product safety, potency, and reliability.
Leveraging cutting-edge Laser Force Cytology™ (LFC) technology, Radiance® offers comprehensive monitoring of cellular starting material and precise quantification of production processes and potency, including the ability to track and optimize cell expansion in real time.
This advanced analytical solution allows researchers to gain valuable insights into cellular responses, including cell health, expansion, activation, differentiation, and killing efficiency, facilitating a deeper understanding of cellular behavior across important process development and production steps.
Radiance® ensures highly precise measurements, offering developers a more detailed understanding of cellular responses and enhancing the overall characterization of cellular behavior. This capability enables manufacturers and production scientists to rapidly assess the quality of cellular starting materials while also enabling the optimization of key production processes across complex manufacturing steps.
By providing real-time insights into cell conditions, Radiance® saves valuable time and resources, ensuring life saving treatments are delivered faster to patients in need. This innovative platform is transforming the field of cell therapy analysis, ensuring higher product consistency and quality, and paving the way for the development of safe and effective therapies.
Rapid and Real-Time Analysis
LumaCyte’s Radiance® instrument employs Laser Force Cytology™ (LFC) technology for immediate and continuous monitoring of cellular response from starting material qualification to expansion, activation, differentiation, and potency.
Label-Free Measurements
Radiance® provides label-free analysis, eliminating the need for external markers and allowing developers to focus on the intrinsic biological innate properties of cells.
High Precision
Radiance® delivers high-precision measurements that ensure consistent and reproducible assay results across complex cell therapy workflows, including stem cell and CAR T-based manufacturing. From cell viability assays to potency evaluations, Radiance® empowers reliable and robust therapeutic outcomes through validated, real-time analytics—driving consistency, safety, and confidence in advanced biologic production.
Laser Force Cytology™ (LFC) is transforming cell therapy analytics through its real-time, label-free precision measurement of cellular responses. This enables rapid optimization of production processes, ensuring consistent product quality, and improved understanding of cellular behavior, ultimately leading to safer and more effective cell-based therapies.
Understanding Macrophage Behavior Using Laser Force Cytology™
Macrophages play a vital role in cell therapy development as key regulators of the immune system, influencing the success and efficacy of therapeutic interventions. They are also being investigated as immunotherapies themselves through the development of CAR-M cell therapies. Understanding and manipulating macrophage behavior is essential for creating strategies that optimize the interaction between transplanted cells and the host environment, ensuring improved tolerance and longevity of cell therapies.
LumaCyte’s Laser Force Cytology™ excels in characterizing macrophages by providing nuanced insights that traditional flow cytometry methods may overlook. Through its label-free, single-cell analysis capabilities, Laser Force Cytology™ reveals intricate details in macrophage behavior, allowing for the detection of subtle analytics that might go unnoticed using conventional techniques.
Take the Next Step in Cell Therapy Analytics
LumaCyte’s expertise in label-free, single-cell analysis instrumentation, powered by Laser Force Cytology™ (LFC) , helps redefine the quality of cell therapies worldwide. Whether you’re developing autologous CAR-T treatments or manufacturing allogeneic or stem cell therapies, Radiance® provides the precision, efficiency, and insight you need to succeed.
Ready to revolutionize your processes? Let’s talk!
